spasticity spasticity
play

3/10/2012 Overview Medication Management of Definition of Spasticity Spasticity in the Traumatic Brain Oral Medications Injured Patient Central acting Peripheral acting Dosage, Mechanism of Action, Side effects Chad Walters,

0 downloads 3 Views 123 KB Size Report
  1. 3/10/2012 Overview Medication Management of • Definition of Spasticity Spasticity in the Traumatic Brain • Oral Medications Injured Patient – Central acting – Peripheral acting • Dosage, Mechanism of Action, Side effects Chad Walters, D.O. • Local treatments Medical Director – Botulinum toxin – Phenol Radical Rehab Solutions • Mechanism of Action, Side effects • Intrathecal Baclofen – Mechanism of action, side effects 6 th Annual Northern Kentucky TBI Conference March 23, 2012 www.bridgesnky.org Spasticity Spasticity • Definition • Treatments – Velocity dependent resistant to stretch resulting in – Oral Medications abnormally increased tone • Central Acting • Mechanism • Peripheral Acting – Uninhibited spinal reflex activity leading to – Local Medications increase in muscle tone and deep tendon reflexes • Botulinum toxin – Gamma Amino Butyric Acid (GABA) is most • Phenol neurolysis abundant CNS inhibitory NT and controls the – Intrathecal Baclofen spinal reflex activity • Deficient in TBI patient Spasticity Oral Medications • Oral Medications • Central acting agents – Central acting agents – Baclofen 20-80mg daily divided twice to three • Baclofen times daily • Tizandine (Zanaflex) • GABA agonist which inhibits spinal reflex activity leading to decreased muscle tone • Diazepam (Valium) • Side effects: weakness, lethargy, somnolence, confusion, ataxia, hallucinations, lowers threshold for seizure activity, withdrawal syndrome 1

  2. 3/10/2012 Oral Medications Oral Medications • Central acting agents • Central acting agents – Tizanidine 6-36mg daily divided three times per – Benzodiazepines day – Diazepam (Valium) 2-10mg BID to TID – Clonazepam 0.5-2mg BID to TID • Alpha adrenergic agonist which binds to spinal cord • Enhances affinity for GABA in the CNS (brain > SC) receptors inhibiting spinal cord reflexes • Enhances pre and post synaptic inhibition at the SC • Side effects: weakness, sedation, dizziness, dry mouth, • Side effects: Sedation, fatigue, habituation, impairment hypotension of motor recovery • Should only be used in severe cases Oral Medications Local Treatments • Peripheral acting agents • Botulinum toxin – Dantrolene 50-300mg daily divided BID to QID – Type A and B • Phenol • Inhibits Ca release from the sarcoplasmic reticulum which is required for muscle contraction • Side effects: weakness, dizziness, drowsiness, hepatotoxicity Local Treatments Local Treatments • Botulinum toxin • Botulinum toxin – Chemical neurotoxin produced by Clostridium – Onset within 12-72 hours botulinum bacterium – Duration ~ 3 months – Type A (Botox) inhibits release of acetylcholine by – Best results if localization techniques used binding to SNAP-25 receptor on presynaptic • EMG guidance membrane • Ultrasound – Type B (Myobloc) inhibits release of acetylcholine • Electrical stimulation by binding to synaptobrevin receptor on – Dosage differs between Type A and B and is presynaptic membrane physician dependent 2

  3. 3/10/2012 Local Treatments Local Treatments • Phenol • Phenol – More challenging than botulinum toxin injections – Chemically destroys the nerve at the – Lower cost neuromuscular junction – Technical issues – Non-selective – Used for large muscle groups only – Causes muscle tissue destruction and atrophy – Onset: Immediate – Duration: 1-36 months – Side effects: Dysesthesias, Marked muscle pain, peripheral edema, extensive motor weakness Intrathecal Baclofen Intrathecal Baclofen • Pros : • GABA agonist – Flexibility in dosing to allow tailoring to patient’s – Decreases neural activity at the spinal cord level needs • Surgically implanted pump in the – Beneficial for UE and LE, large and small muscle subcutaneous tissue in lower abdomen groups – Rarely leads to weakness in unaffected muscles • Rubber catheter that runs from pump to CSF • Cons : at the spinal cord – Surgical procedure – Patient selection must be a careful process – Overdose and Withdrawal syndromes Intrathecal Baclofen Baclofen Overdose • Side effects : • Causes – Hypotonia – Programming errors – Somnolence • Incorrect concentration used – Nausea/vomiting • Large dose increases – Dizziness • Switching from continuous to bolus dosing – Urine retention – Failure to wean oral medications with increases in – Constipation pump dosage – Withdrawal – Overdose 3

  4. 3/10/2012 Baclofen Overdose Baclofen Overdose • Hypotension • Treatment • Hypotonia – Emergency – call 911 – Respiratory support – Increased weakness from baseline – Determine cause and reverse • Significant somnolence • Respiratory depression • Death Baclofen Withdrawal Baclofen Withdrawal • Causes • Rigidity/Clonus – Empty pump • Itching without presence of a rash – Pump failure • Hallucinations • Battery expires (5-7 years from implant) • Motor malfunction • Seizures – Catheter problems • Fever/Malignant Hyperthermia • Kinking • Breakage – Temperatures often > 106 degrees • Separation from pump • Occlusion • Migration from CSF space Baclofen Withdrawal Summary • Treatment • Treatment of spasticity requires multidisciplinary approach including PT, OT and medications – IV Benzodiazepines • Selection of medications should be patient • Valium 10mg – Cooling blankets specific depending on co-morbidities and deficits – Dantrolene for malignant hyperthermia • Oral medications should be attempted prior to local or invasive treatments • Good practice to know what medications are used for spasticity, their dosages, mechanisms of action and side effects 4

  5. 3/10/2012 References • Braddom, et al. Physical Medicine and Rehabilitation. 3 rd Edition. pp 651-662 • Zafonte, et al. Brain Injury Medicine. pp 615- 651 5

Recommend Documents


1
1 UPPER EXTREMITY SPASTICITY UPPER

Pharmacist 1 UPPER EXTREMITY SPASTICITY UPPER EXTREMITY CONTINUED

1
1 POST -STROKE SPASTICITY PREVALENCE

ADULT POST-STROKE SPASTICITY Presented by: Paul J. Stacey Hons MBBS, MSc.

spasticity a 2017 a potential new treatment for spasticity
Spasticity, A. (2017). A

Spasticity, A. (2017). A potential new treatment for spasticity

1 2
1 2 BOTULINUM TOXIN NEEDLE GUIDANCE

Injection Therapies 1 2 BOTULINUM TOXIN NEEDLE GUIDANCE EMG / E. STIM

hand held device to reduce spasticity
Hand-held Device to Reduce Spasticity

Hand-held Device to Reduce Spasticity Advisor: Tracy Puccinelli Client: Carol

vera needham email tubeefit yahoo ca
Vera Needham Email: tubeefit@yahoo.ca

Vera Needham Email: tubeefit@yahoo.ca The goal of Tubee Training is to help

merz safe post stroke spasticity project six month update
Merz/SAFE Post Stroke Spasticity

Merz/SAFE Post Stroke Spasticity Project. Six Month Update Nicole

and managing information in
and managing information in the

SCHOOL OF PUBLIC HEALTH AND PREVENTIVE MEDICINE Experiences with navigating

abstract sample scientific presentation title comparing
Abstract Sample Scientific

Abstract Sample Scientific Presentation Title: Comparing Ultrasound-guided

chronic pain and neurology
Chronic Pain and Neurology An

Chronic Pain and Neurology An Approach to Complex Patients with Intractable

neuromuscular junction paralysis in the surgical patient
Neuromuscular Junction Paralysis in

Neuromuscular Junction Paralysis in the Surgical Patient: Too Much of a Good

pesticide m anagement in the field and its relevance to
Pesticide M anagement in the Field and

Pesticide M anagement in the Field and Its Relevance to Residues in Feed

recreational cannabis current safety considerations
Recreational Cannabis: Current Safety

Recreational Cannabis: Current Safety Considerations Lake Ontario Regional

research update on adult me cfs
Research Update on Adult ME/CFS Lily

Research Update on Adult ME/CFS Lily Chu, MD, MSHS Stanford ME/CFS Advisory

david walker university of arizona environmental research
David Walker University of Arizona,

David Walker University of Arizona, Environmental Research Laboratory

engineering cellular nanorobots
Engineering Cellular Nanorobots Robots

Engineering Cellular Nanorobots Robots extend our capabilities Mars rover

neuroscience and consciousness
Neuroscience and Consciousness

Neuroscience and Consciousness Chapter 2 Neurons Neuron cell

sundown syndrome nhsggc primary care palliative care team
Sundown Syndrome NHSGGC Primary Care

Sundown Syndrome NHSGGC Primary Care Palliative Care Team Tel: 0141 427 8254

fingolimod on visual system deficits in alzheimer s
FINGOLIMOD ON VISUAL SYSTEM DEFICITS

INVESTIGATING THE NEUROPROTECTIVE EFFECTS OF FINGOLIMOD ON VISUAL SYSTEM

dementia
Dementia Aetiology, pathophysiology

Dementia Aetiology, pathophysiology and the role of neuropsychological

ab2 quot 18 quot 6 quot c922 de f2 quot c8 82 quot 08 9 8

AB2":*?(18"+6"C922?DE(F2"

psychiatric mimics
Psychiatric Mimics The Interface of

Psychiatric Mimics The Interface of Psychiatry and Medicine Dr. Devina